

Attorney Docket No.: 3556.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Confirmation No: 5207

Serial No.: 09/056,343

Group Art Unit: 1652

Filed: April 7, 1998

Examiner: W. Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

FAX RECEIVED

OCT 10 2002

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

OFFICIAL

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner W. Moore, fax number (703) 308-4242.

Respectfully submitted,

Date: October 9, 2002



Elias J. Lambiris
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 3556.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Confirmation No: 5207

Serial No.: 09/056,343

Group Art Unit: 1652

Filed: April 7, 1998

Examiner: W. Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

AMENDMENT FEE TRANSMITTALCommissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed April 9, 2002.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from July 9, 2002 to October 9, 2002. The required fee for the extension is estimated to be \$920.

The fee for claims has been calculated as shown below:

Total: $29 - 20 = 9 \times 18 = \162 Independent: $4 - 3 = 1 \times 84 = \$84$

Total additional fee for claims required is \$246.

Please charge the required extension and claims fees, estimated to be \$1,166, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: October 9, 2002



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

#22/D
Dmt
10-16-02

Attorney Docket No.: 3556.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Confirmation No: 5207

Serial No.: 09/056,343

Group Art Unit: 1652

Filed: April 7, 1998

Examiner: W. Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed April 9, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please add new claims 67-76:

67. A method for producing a DNA molecule encoding a variant of a reference protein having a known amino acid sequence, comprising

(a) mapping one or more epitopes of the reference protein with immunological and proteochemical techniques wherein the reference protein and variants thereof are used for the production of antibodies; and

(b) forming a DNA molecule encoding the amino acid sequence of the variant, which has an altered amino acid sequence of one or more epitopes of the reference protein, wherein the variant evokes a lower immunogenic response in an animal than the reference protein.

68. The method of claim 67, wherein the DNA molecule is formed by mutating a DNA molecule encoding the amino acid sequence of the reference protein to alter the amino acid sequence of one or more epitopes.

10/16/2002 PROSP 0150276 09056343
01 FC:1201 84.00 CH
02 FC:1202 162.00 CH
03 FC:1253 920.00 CH